Guardant Health Inc (NASDAQ: GH)’s stock price has increased by 12.81 compared to its previous closing price of 35.84. However, the company has seen a -2.53% decrease in its stock price over the last five trading sessions. businesswire.com reported 2025-02-28 that PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that on February 11, 2025, the Compensation Committee of Guardant’s Board of Directors approved the granting of restricted stock units (“RSUs”) representing 110,681 shares of its common stock to 102 new non-executive employees and one non-qualified stock option award to purchase 22,091 shares of its common stock to one new non-executive employee with a grant date of Febr.
Is It Worth Investing in Guardant Health Inc (NASDAQ: GH) Right Now?
The stock has a 36-month beta value of 1.53. Opinions on the stock are mixed, with 14 analysts rating it as a “buy,” 7 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for GH is 118.00M, and at present, short sellers hold a 6.64% of that float. On March 11, 2025, the average trading volume of GH was 2.27M shares.
GH’s Market Performance
The stock of Guardant Health Inc (GH) has seen a -2.53% decrease in the past week, with a -9.08% drop in the past month, and a 8.95% gain in the past quarter. The volatility ratio for the week is 7.67%, and the volatility levels for the past 30 days are at 6.76% for GH. The simple moving average for the past 20 days is -6.29% for GH’s stock, with a 27.94% simple moving average for the past 200 days.
Analysts’ Opinion of GH
Many brokerage firms have already submitted their reports for GH stocks, with Barclays repeating the rating for GH by listing it as a “Overweight.” The predicted price for GH in the upcoming period, according to Barclays is $60 based on the research report published on January 23, 2025 of the current year 2025.
Guggenheim, on the other hand, stated in their research note that they expect to see GH reach a price target of $36. The rating they have provided for GH stocks is “Buy” according to the report published on June 28th, 2024.
Jefferies gave a rating of “Buy” to GH, setting the target price at $32 in the report published on June 03rd of the previous year.
GH Trading at -3.23% from the 50-Day Moving Average
After a stumble in the market that brought GH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -20.55% of loss for the given period.
Volatility was left at 6.76%, however, over the last 30 days, the volatility rate increased by 7.67%, as shares sank -9.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +26.67% upper at present.
During the last 5 trading sessions, GH fell by -3.59%, which changed the moving average for the period of 200-days by +61.45% in comparison to the 20-day moving average, which settled at $43.12. In addition, Guardant Health Inc saw 32.34% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at GH starting from Joyce Meghan V., who sale 100 shares at the price of $42.71 back on Mar 03 ’25. After this action, Joyce Meghan V. now owns 7,647 shares of Guardant Health Inc, valued at $4,271 using the latest closing price.
Joyce Meghan V., the Director of Guardant Health Inc, proposed sale 100 shares at $42.71 during a trade that took place back on Mar 03 ’25, which means that Joyce Meghan V. is holding shares at $4,271 based on the most recent closing price.
Stock Fundamentals for GH
Current profitability levels for the company are sitting at:
- -0.6 for the present operating margin
- 0.61 for the gross margin
The net margin for Guardant Health Inc stands at -0.59. The total capital return value is set at -0.35. Equity return is now at value -4584.47, with -26.67 for asset returns.
Based on Guardant Health Inc (GH), the company’s capital structure generated 1.12 points at debt to capital in total, while cash flow to debt ratio is standing at -0.18. The debt to equity ratio resting at -9.57. The interest coverage ratio of the stock is -171.87.
Currently, EBITDA for the company is -390.12 million with net debt to EBITDA at -2.08. When we switch over and look at the enterprise to sales, we see a ratio of 7.85. The receivables turnover for the company is 6.7for trailing twelve months and the total asset turnover is 0.5. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.68.
Conclusion
To sum up, Guardant Health Inc (GH) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
